Javier Quesada
Family Medicine · Long Beach, CANPI 1215929880
Payments from drug & device makers
Across 158 payments — averaging $34.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Gilead$805
- Johnson & Johnson$502
- Amgen$501
- Astellas Pharma US Inc$346
- Lilly USA, LLC$345
- plus $2K from 19 others
What the payments were for
- Food & beverage$5,40299%
- Education$661%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 45 | $1,357 |
| Gilead | 20 | $805 |
| Johnson & Johnson | 12 | $502 |
| Amgen | 9 | $501 |
| Astellas Pharma US Inc | 10 | $346 |
| Lilly USA, LLC | 17 | $345 |
| Boehringer Ingelheim | 3 | $235 |
| Abbott | 2 | $188 |
| Ardelyx, Inc. | 3 | $162 |
| Idorsia Pharmaceuticals US Inc | 3 | $158 |
| Bayer | 8 | $148 |
| Sanofi Pasteur Inc. | 2 | $111 |
| Kowa Pharmaceuticals America, Inc. | 5 | $106 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $86 |
| Alkermes, Inc. | 4 | $84 |
| Merck | 3 | $64 |
| Dexcom, Inc. | 1 | $55 |
| Pfizer | 2 | $47 |
| Phadia US Inc. | 2 | $38 |
| CSL Behring | 1 | $31 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $27 |
| AstraZeneca | 1 | $24 |
| Hologic Sales And Service, LLC | 1 | $19 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| Indivior Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Repatha$396
- Vemlidy$372
- Wegovy$363
- FREESTYLE LIBRE 3$160
- IBSRELA$125
- Veozah$125
- QUVIVIQ$125
- XARELTO$122
- Ozempic$121
- JARDIANCE$120
- INVEGA SUSTENNA$120
- INVEGA TRINZA$120
- RYBELSUS$113
How this compares
$5,468 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 131 | $111,483 |
| RybelsusSemaglutide | 84 | $90,686 |
| OzempicSemaglutide | 86 | $76,756 |
| FarxigaDapagliflozin Propanediol | 34 | $22,324 |
| JanuviaSitagliptin Phosphate | 27 | $21,850 |
| Repatha SureclickEvolocumab | 12 | $6,402 |
| Humalog Kwikpen U-100Insulin Lispro | 25 | $3,745 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $3,567 |
| Atorvastatin Calcium | 335 | $3,241 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 71 | $2,486 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 31 | $1,965 |
| Metformin Hcl | 211 | $1,351 |
| Humulin 70-30Insulin Nph Hum/Reg Insulin Hm | 11 | $1,163 |
| Tamsulosin Hcl | 75 | $1,130 |
| Fluticasone Propionate | 89 | $947 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus, Ozempic | $1,357 | $167,442170 claims |
| Boehringer IngelheimJardiance | $235 | $111,483131 claims |
| AstraZenecaFarxiga | $24 | $22,32434 claims |
| MerckJanuvia | $64 | $21,85027 claims |
| Lilly USA, LLCHumulin 70-30 | $345 | $1,16311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.
Other family medicine in Long Beach
- Steven ReynoldsLong Beach$53M
- Jack VuLong Beach$10.1M
- Amina HaggagNorthridge$112.8M
- Rizwana MohseniLake Forest$26.7M
- Daniel JohnsonSan Diego$15.7M
- Stacey LayleSan Diego$14.8M
- Apinya VutikullirdCypress$14.3M
- Hanid AudishSpring Valley$13.6M
- Augusto FocilOxnard$12.6M
- Suzanne FussellOxnard$8.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.